• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卡介苗诱导的外周免疫反应的发展提示了浅表性膀胱癌需要延长卡介苗治疗时间。

[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].

作者信息

Shekarsarai H, Zlotta A R, Drowart A, Van Vooren J P, De Cock M, Pirson M, Palfliet K, Jurion F, Vanonckelen A, Simon J, Schulman C C, Huygen K

机构信息

Département dUrologie, Hôpital Universitaire Erasme, Bruxelles, Belgique.

出版信息

Acta Urol Belg. 1997 Mar;65(1):1-4.

PMID:9245197
Abstract

Optimal duration of immunotherapy treatment by BCG for the prevention of recurrences of superficial bladder cancer is still unknown. We have studied the evolution and duration of the cellular immunity response at the peripheral level after BCG intravesical instillations. Our results show that immunity activation after BCG is of short duration and don't take more than 6 months. Our results support, strengthen and partially allow to explain the utility of maintenance treatment by BCG following 6-weekly instillations.

摘要

卡介苗免疫疗法预防浅表性膀胱癌复发的最佳疗程仍不明确。我们研究了卡介苗膀胱内灌注后外周水平细胞免疫反应的演变及持续时间。我们的结果显示,卡介苗免疫激活持续时间较短,不超过6个月。我们的结果支持、强化并部分解释了每6周灌注一次后进行卡介苗维持治疗的效用。

相似文献

1
[The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].卡介苗诱导的外周免疫反应的发展提示了浅表性膀胱癌需要延长卡介苗治疗时间。
Acta Urol Belg. 1997 Mar;65(1):1-4.
2
[Immunotherapy in superficial bladder carcinoma].[浅表性膀胱癌的免疫治疗]
Arch Esp Urol. 2000 Dec;53(10):879-92.
3
Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.经尿道切除浅表性膀胱癌后卡介苗的免疫预防性膀胱内应用。
Croat Med J. 2003 Apr;44(2):187-92.
4
[Bacillus of Calmette-Guérin immunotherapy: which protocol?].[卡介苗免疫疗法:采用哪种方案?]
Prog Urol. 2008 May;18 Suppl 5:S99-104. doi: 10.1016/S1166-7087(08)72485-0.
5
[Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].卡介苗联合抗纤溶药物膀胱灌注预防膀胱癌复发的临床研究
Zhonghua Wai Ke Za Zhi. 2005 Nov 15;43(22):1457-60.
6
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.卡介苗维持免疫疗法用于复发性TA、T1期及原位膀胱移行细胞癌:西南肿瘤协作组的一项随机研究
J Urol. 2000 Apr;163(4):1124-9.
7
Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.高危浅表性膀胱癌的再次经尿道切除术可改善对卡介苗治疗的初始反应。
J Urol. 2005 Dec;174(6):2134-7. doi: 10.1097/01.ju.0000181799.81119.fc.
8
Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.浅表性膀胱癌卡介苗膀胱内灌注治疗期间针对结核菌素和抗原85复合物的细胞和体液反应的演变
Acta Urol Belg. 1994 Sep;62(3):63-8.
9
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).卡介苗与表柔比星治疗原发性、继发性或同时性膀胱原位癌:欧洲癌症研究与治疗组织-泌尿生殖组III期试验(30906)的结果
J Urol. 2005 Feb;173(2):405-9. doi: 10.1097/01.ju.0000150425.09317.67.
10
Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.尿白细胞介素-8和18可预测浅表性膀胱癌对卡介苗膀胱内灌注治疗的反应。
J Urol. 2000 Dec;164(6):2129-33.